|Day Low/High||98.78 / 100.79|
|52 Wk Low/High||56.20 / 103.03|
Retrophin (RTRX), the biotech company that used to be run by indicted hedge fund manager Martin Shkreki, provides an interesting investment opportunity.
Jim Cramer says don’t rush into the stock market in Monday's trading session looking for bargains in the midst of a selloff.
Jim Cramer, portfolio manager at TheStreet’s Action Alerts PLUS and host of CNBC’s ‘Mad Money’ said Amazon (AMZN) stock is going higher because the company’s business model is so good.
Jim Cramer says Microsoft (MSFT) will report a decent quarter, thanks to Windows 10, but he wishes the company would make an acquisition.
A so-called "pyramid strategy" can help you enter the depressed sector.
Materials and technology names led the way down on the session.
Only one fund category (of 20) has beaten the S&P 500 over half a decade.
Even if you are a raging bull, it is still tricky to navigate this market.
Here are five large purchases that were made by hedge funds recently.
There is no reason to believe the market is topping out. It just needs to digest its gains.
Adam Feuerstein, senior columnist for TheStreet, says Amarin and Onyx are the next big things in biotech.